BiotechTube

Pembrolizumab + Enfortumab Vedotin

Phase 3Active
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urinary Bladder Cancer, Muscle-invasive

Conditions

Urinary Bladder Cancer, Muscle-invasive

Trial Timeline

Jul 24, 2019 → Dec 15, 2027

NCT ID
NCT03924895

About Pembrolizumab + Enfortumab Vedotin

Pembrolizumab + Enfortumab Vedotin is a phase 3 stage product being developed by Astellas Pharma for Urinary Bladder Cancer, Muscle-invasive. The current trial status is active. This product is registered under clinical trial identifier NCT03924895. Target conditions include Urinary Bladder Cancer, Muscle-invasive.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03924895Phase 3Active

Competing Products

20 competing products in Urinary Bladder Cancer, Muscle-invasive

See all competitors
ProductCompanyStageHype Score
Duloxetine + placeboEli LillyPhase 2
52
DuloxetineEli LillyPhase 2
52
Enfortumab vedotinAstellas PharmaPhase 1
33
solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
85
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
52
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
85
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaPre-clinical
23
TamuslosinAstellas PharmaPhase 3
77
Tamsulosin + SolifenacinAstellas PharmaApproved
85
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placeboAstellas PharmaPhase 3
77
solifenacin succinate + tolterodineAstellas PharmaPhase 3
77
TamusulosinAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
77
Solifenacin succinate + PlaceboAstellas PharmaPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85